Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
oleh: Veronica Di Cristanziano, Patrick Affeldt, Moritz Trappe, Maike Wirtz, Eva Heger, Elena Knops, Rolf Kaiser, Dirk Stippel, Roman-Ulrich Müller, Udo Holtick, Christoph Scheid, Martin Kann, Christine E. Kurschat, Franziska Grundmann
| Format: | Article |
|---|---|
| Diterbitkan: | MDPI AG 2021-08-01 |
Deskripsi
The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.